Bioluminescence for USP sterility testing of pharmaceutical suspension products.
AUTOR(ES)
Bussey, D M
RESUMO
Bioluminescence measurement significantly improved the accuracy, sensitivity, precision, and reliability of the current visual endpoint determination for the USP sterility test and eliminated the day 7 transfer/dilution step required for testing suspension products. Thirteen strains of bacteria and fungi (representing potential contaminants in sterile products), three pharmaceutical suspension products, and four media were used in the experiment. No interference from suspension products was encountered in the detection of microbial growth by the bioluminescence measurement. The poor fungal growth encountered was attributed to insufficient diffusion of oxygen into the medium and was circumvented by use of a large tube size (38 by 200 mm) or by vortexing the medium once during the 2-week incubation period. Bioluminescence measurement would facilitate automated handling of the sterility test endpoint readout operation. The optimum parameters of bioluminescence measurement for application in sterility testing were determined.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=238872Documentos Relacionados
- Correlation of in vitro challenge testing with consumer use testing for cosmetic products.
- Testing new pharmaceutical products in children
- Application of the BacT/ALERTR 3D system for sterility testing of injectable products
- Simplified method for confirmation of PCR products.
- Identification of genes and gene products necessary for bacterial bioluminescence.